Home / Business and Economy / J&J Bets Big on Sail Bio for Immune Disease Cure
J&J Bets Big on Sail Bio for Immune Disease Cure
30 Jul
Summary
- Johnson & Johnson is partnering with Sail Biomedicines.
- The collaboration focuses on developing CAR-T therapies.
- J&J will make substantial initial payments totaling $785 million.
Johnson & Johnson has entered into a significant collaboration with Sail Biomedicines, a privately held company, to advance the development of CAR-T therapies. These therapies are intended for the treatment of immune-mediated diseases, a group of conditions where the immune system mistakenly attacks the body's own tissues.
Under the terms of this agreement, Johnson & Johnson is set to make considerable initial payments to Sail Biomedicines. These payments aggregate to $785 million and encompass an equity investment in the company. This financial commitment underscores J&J's strategic focus on pioneering new treatments for debilitating autoimmune disorders through cutting-edge cell therapy research.
